BMTI / Biomimetic Therapeutics, Inc. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

BMTI / Biomimetic Therapeutics, Inc. / AQR CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioMimetic Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09064X101 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic

- 15-12G

15-12G OMB APPROVAL OMB Number: 3235-0167 Expires: December 31, 2014 Estimated average burden hours per response ………1.

POWER OF ATTORNEY

EX-99.B Exhibit B POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS: The undersigned, Douglas C. Fisher, hereby constitutes and appoints Karen A. Wilson as his true and lawful Attorney-in-Fact, with full power in his name and on his behalf, to take all actions and do all things necessary with respect to all matters arising in connection with the ownership reporting requirements of the securities laws o

BMTI / Biomimetic Therapeutics, Inc. / INTERWEST PARTNERS VIII LP - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Joint Filing Statement

EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D is filed on behalf of each of us. Date: March 13, 2013 INTERWEST PARTNERS VIII, L.P. By: /s/ Karen A. Wilson Karen A. Wilson as Attorney-in-fact By: InterWest Management Partners VIII, L.L.C. for Harvey B. Cash Its: General Partner By: /s/ W. Stephen Holmes By: /s/ Karen A. Wil

- AMENDMENT NO. 1

AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-135505 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-168104 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 3

- AMENDMENT NO. 1

As filed with the Securities and Exchange Commission on March 11, 2013 Registration No.

- POS AM

As filed with the Securities and Exchange Commission on March 11, 2013 Registration No.

- POS AM

POS AM As filed with the Securities and Exchange Commission on March 11, 2013 Registration No.

- AMENDMENT NO.1

As filed with the Securities and Exchange Commission on March 11, 2013 Registration No.

- AMENDMENT NO.1

AMENDMENT NO.1 As filed with the Securities and Exchange Commission on March 11, 2013 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-135505 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-168104 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 33

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 1, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation) (C

Submission of Matters to a Vote of Security Holders

8-K 1 v3361988k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 26, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction o

BMTI / Biomimetic Therapeutics, Inc. / AQR CAPITAL MANAGEMENT LLC - AQR CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioMimetic Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09064X101 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

BMTI / Biomimetic Therapeutics, Inc. / Clearbridge Investments, LLC - BIOMIM Passive Investment

Securities and Exchange Commission Washington, D. C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 ) BioMimetic Therapeutics Inc Common Stock CUSIP Number 09064X101 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1(b) [ ] Rule 13d-1(c) [

- DEFA 14A

DEFA 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to § 240.

Other Events

8-K 1 d483111d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 12, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdic

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 5, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation) (Commiss

- BIOMIMETIC THERAPEUTICS, INC. - DEFM 14A

BioMimetic Therapeutics, Inc. - DEFM 14a Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only

Other Events

8-K 1 v3320158k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Juri

Merger Prospectus - FORM 425

Form 425 Filed by Wright Medical Group, Inc. Commission File No. 000-32883 Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange of 1934 Subject Company: BioMimetic Therapeutics, Inc. Commission File No.: 000-51934 This filing relates to the proposed acquisition by Wright Medical Group, Inc., a Delaware corporation (“Wright”), of Bio

Other Events - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation) (Commission File Nu

BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial Product Candidate Aimed at Large Tendinosis Market

Press Release of BioMimetic Therapeutics, Inc. Exhibit 99.1 Contact: Kearstin Patterson Senior Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial Product Candidate Aimed at Large Tendinosis Market Franklin, Tenn. – January 3, 2013 – BioMimetic

Financial Statements and Exhibits, Other Events

8-K 1 d460803d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdicti

BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial Product Candidate Aimed at Large Tendinosis Market

Press Release of BioMimetic Therapeutics, Inc. Exhibit 99.1 Contact: Kearstin Patterson Senior Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial Product Candidate Aimed at Large Tendinosis Market Franklin, Tenn. – January 3, 2013 – BioMimetic

- FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2013 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation)

RETENTION AGREEMENT

EX-10.3 Exhibit 10.3 RETENTION AGREEMENT This RETENTION AGREEMENT (this “Agreement”) is made and entered into as of the 19th day of December, 2012 (the “Effective Date”) by and between BioMimetic Therapeutics, Inc. (the “Company”) and Russ Pagano (the “Executive” and, with the Company, the “Parties”). WHEREAS, the Company has entered into a merger agreement dated November 19, 2012, by and among Wr

RETENTION AGREEMENT

EX-10.1 2 d458184dex101.htm EX-10.1 Exhibit 10.1 RETENTION AGREEMENT This RETENTION AGREEMENT (this “Agreement”) is made and entered into as of the 20th day of December, 2012 (the “Effective Date”) by and among BioMimetic Therapeutics, Inc. (the “Company”), Wright Medical Group, Inc., a Delaware corporation (the “Parent”) and Dr. Samuel E. Lynch (the “Executive” and, with the Company and the Paren

RETENTION AGREEMENT

EX-10.3 4 d458184dex103.htm EX-10.3 Exhibit 10.3 RETENTION AGREEMENT This RETENTION AGREEMENT (this “Agreement”) is made and entered into as of the 19th day of December, 2012 (the “Effective Date”) by and between BioMimetic Therapeutics, Inc. (the “Company”) and Russ Pagano (the “Executive” and, with the Company, the “Parties”). WHEREAS, the Company has entered into a merger agreement dated Novemb

- 8-K

DEFA14A 1 d458184d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdict

RETENTION AGREEMENT

EX-10.2 Exhibit 10.2 RETENTION AGREEMENT This RETENTION AGREEMENT (this “Agreement”) is made and entered into as of the 20th day of December, 2012 (the “Effective Date”) by and between BioMimetic Therapeutics, Inc. (including its successors, the “Company”) and Larry Bullock (the “Executive” and, with the Company, the “Parties”). WHEREAS, the Company has entered into a merger agreement dated Novemb

RETENTION AGREEMENT

EX-10.2 Exhibit 10.2 RETENTION AGREEMENT This RETENTION AGREEMENT (this “Agreement”) is made and entered into as of the 20th day of December, 2012 (the “Effective Date”) by and between BioMimetic Therapeutics, Inc. (including its successors, the “Company”) and Larry Bullock (the “Executive” and, with the Company, the “Parties”). WHEREAS, the Company has entered into a merger agreement dated Novemb

RETENTION AGREEMENT

EX-10.1 Exhibit 10.1 RETENTION AGREEMENT This RETENTION AGREEMENT (this “Agreement”) is made and entered into as of the 20th day of December, 2012 (the “Effective Date”) by and among BioMimetic Therapeutics, Inc. (the “Company”), Wright Medical Group, Inc., a Delaware corporation (the “Parent”) and Dr. Samuel E. Lynch (the “Executive” and, with the Company and the Parent, the “Parties”). WHEREAS,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation) (Co

Merger Prospectus - 425

425 1 d452550d425.htm 425 Filed by Wright Medical Group, Inc. Commission File No. 000-32883 Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange of 1934 Subject Company: BioMimetic Therapeutics, Inc. Commission File No.: 000-51934 This filing relates to the proposed acquisition by Wright Medical Group, Inc., a Delaware corporation (

POWER OF ATTORNEY

EX-99.5 3 d451403dex995.htm EXHIBIT 5 Exhibit 5 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS: The undersigned, Keval Desai, hereby constitutes and appoints Karen A. Wilson as his true and lawful Attorney-in-Fact, with full power in his name and on his behalf, to take all actions and do all things necessary with respect to all matters arising in connection with the ownership reporting requirements

Joint Filing Statement

Exhibit 4 EXHIBIT 4 Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D is filed on behalf of each of us.

POWER OF ATTORNEY

EX-99.6 4 d451403dex996.htm EXHIBIT 6 Exhibit 6 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS: The undersigned, W. Scott Hedrick, hereby constitutes and appoints Karen A. Wilson as his true and lawful Attorney-in-Fact, with full power in his name and on his behalf, to take all actions and do all things necessary with respect to all matters arising in connection with the ownership reporting requirem

BMTI / Biomimetic Therapeutics, Inc. / INTERWEST PARTNERS VIII LP - SC 13D/A Activist Investment

SC 13D/A 1 d451403dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIOMIMETIC THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 09064X101 (CUSIP Number) W. Stephen Holmes III InterWest Partners 2710 Sand Hill Road, Second Fl

BMTI / Biomimetic Therapeutics, Inc. / Novo Holdings A/S Activist Investment

begin 644 schedule13da.pdf M)5!$1BTQ+C0-)>+CS],-"C0Y(#`@;V)J#3P\+TQI;F5A"Q8,=5(2"R8@5&D`ZB'HP.HA(.!48"!P:6!(13,0#$& M*"W&P%`.,HH;B/G`MOHR\'!,;.8ZP-#W:2-7@M[U!8LY!7S<-\P&2THQ,#38 M@BP&8A`MR%LS,2`Q.%TO1&5C;V1E4&%R;7,\/"]#;VQU M;6YS(#,O4')E9&EC=&]R(#$R/CXO4VEZ92`T.2]4>7!E+UA2968^/G-T-IB8I)D8&)@8*04`P08``\U`%$-"F5N9'-T6]U="]/;F5#;VQU;6XO4W1R=6-T5')E95)O;W0@,S$@ M,"!2+U1Y<&4O0V%T86QO9R],87-T36]D:69I960

BMTI / Biomimetic Therapeutics, Inc. / Novo Holdings A/S Activist Investment

July 20 2009 SD-13A DOC Note: PDF provided as a courtesy UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

BMTI / Biomimetic Therapeutics, Inc. / Wright Medical Group Inc - FORM SC 13D Activist Investment

Form SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BioMimetic Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 09064X101 (CUSIP Number) James A. Lightman, Senior Vice President, General Counsel and Secretary Wright Medical Group, Inc.

Merger Prospectus - 425

425 Filed by Wright Medical Group, Inc. Commission File No. 000-32883 Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange of 1934 Subject Company: BioMimetic Therapeutics, Inc. Commission File No.: 000-51934 This filing relates to the proposed acquisition by Wright Medical Group, Inc., a Delaware corporation (“Wright”), of BioMimet

EMPLOYMENT AGREEMENT

EX-10.3 5 d441762dex103.htm EX-10.3 Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) made effective as of July 17, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Larry Bullock (the “Executive”). In consideration of the mutual covenants contained in this Agreement, the parties hereby agree as follows: 1. Employment. The Compan

EMPLOYMENT AGREEMENT

EX-10.3 5 d441762dex103.htm EX-10.3 Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) made effective as of July 17, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Larry Bullock (the “Executive”). In consideration of the mutual covenants contained in this Agreement, the parties hereby agree as follows: 1. Employment. The Compan

EMPLOYMENT AGREEMENT

EX-10.4 6 d441762dex104.htm EX-10.4 Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) made effective as of July 17, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Russell Pagano (the “Executive”). In consideration of the mutual covenants contained in this Agreement, the parties hereby agree as follows: 1. Employment. The C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation

CONTINGENT VALUE RIGHTS AGREEMENT by and between WRIGHT MEDICAL GROUP, INC. AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC Dated as of [ — ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 Definiti

EX-10.1 3 d441762dex101.htm EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT by and between WRIGHT MEDICAL GROUP, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC Dated as of [ — ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 Definitions 1 SECTION 1.2 Compliance and Opinions 13 SECTION 1.3 Form of Documents Delivered to Trustee 1

Amendment to Employment Agreement

EX-10.5 7 d441762dex105.htm EX-10.5 Exhibit 10.5 Amendment to Employment Agreement THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of November 18, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Samuel Lynch. WITNESSETH WHEREAS, there parties hereto entered into an employment agreement, dated as of July 17, 20

BioMimetic Therapeutics, Inc. Kearstin Patterson Sr. Director Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter Into Agreement to Combine

FOR IMMEDIATE RELEASE Investors and Media: Wright Medical Group, Inc. Julie D. Tracy Sr. Vice President, Chief Communications Officer 901-290-5817 (office) [email protected] BioMimetic Therapeutics, Inc. Kearstin Patterson Sr. Director Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter

Merger Prospectus - FORM 425

Form 425 Filed by Wright Medical Group, Inc. Commission File No. 000-32883 Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange of 1934 Subject Company: BioMimetic Therapeutics, Inc. Commission File No.: 000-51934 This filing relates to the proposed acquisition by Wright Medical Group, Inc., a Delaware corporation (“Wright”), of Bio

- FORM 8-K

DEFA14A 1 d441762d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Juri

FORM OF VOTING AGREEMENT

EX-10.2 4 d441762dex102.htm EX-10.2 Exhibit 10.2 FORM OF VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of November 19, 2012 by and between Wright Medical Group, Inc., a Delaware corporation (“Parent”), and the undersigned Stockholder (the “Stockholder”) of BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”). WITNESSETH: WHEREAS, Parent, Ach

CONTINGENT VALUE RIGHTS AGREEMENT by and between WRIGHT MEDICAL GROUP, INC. AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC Dated as of [ — ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 Definiti

EX-10.1 3 d441762dex101.htm EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT by and between WRIGHT MEDICAL GROUP, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC Dated as of [ — ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 Definitions 1 SECTION 1.2 Compliance and Opinions 13 SECTION 1.3 Form of Documents Delivered to Trustee 1

FORM OF VOTING AGREEMENT

EX-10.2 Exhibit 10.2 FORM OF VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of November 19, 2012 by and between Wright Medical Group, Inc., a Delaware corporation (“Parent”), and the undersigned Stockholder (the “Stockholder”) of BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”). WITNESSETH: WHEREAS, Parent, Achilles Merger Subsidiary, Inc

EMPLOYMENT AGREEMENT

EX-10.4 Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) made effective as of July 17, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Russell Pagano (the “Executive”). In consideration of the mutual covenants contained in this Agreement, the parties hereby agree as follows: 1. Employment. The Company agrees to employ the

Amendment to Employment Agreement

EX-10.5 7 d441762dex105.htm EX-10.5 Exhibit 10.5 Amendment to Employment Agreement THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of November 18, 2012 by and between BioMimetic Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Samuel Lynch. WITNESSETH WHEREAS, there parties hereto entered into an employment agreement, dated as of July 17, 20

Merger Prospectus - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2012 WRIGHT MEDICAL GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 000-32883 13-4088127 (State or other jurisdiction (Commission (IRS Employe

Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter Into Agreement to Combine Businesses Transaction Will Add Breakthrough Biologics Platform and Pipeline to Further Accelerate Growth Opportunities in Wright’s Extremities Business Upfr

EX-99.1 8 d441762dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investors & Media: Wright Medical Group, Inc. Julie D. Tracy Sr. Vice President, Chief Communications Officer 901-290-5817 (office) [email protected] BioMimetic Therapeutics, Inc. Kearstin Patterson Sr. Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] Wright Medical G

Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter Into Agreement to Combine Businesses Transaction Will Add Breakthrough Biologics Platform and Pipeline to Further Accelerate Growth Opportunities in Wright’s Extremities Business Upfr

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investors & Media: Wright Medical Group, Inc. Julie D. Tracy Sr. Vice President, Chief Communications Officer 901-290-5817 (office) [email protected] BioMimetic Therapeutics, Inc. Kearstin Patterson Sr. Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] Wright Medical Group, Inc. and BioMimetic Th

AGREEMENT AND PLAN OF MERGER by and among BIOMIMETIC THERAPEUTICS, INC., WRIGHT MEDICAL GROUP, INC., ACHILLES MERGER SUBSIDIARY, INC. ACHILLES ACQUISITION SUBSIDIARY, LLC Dated as of November 19, 2012

EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among BIOMIMETIC THERAPEUTICS, INC., WRIGHT MEDICAL GROUP, INC., ACHILLES MERGER SUBSIDIARY, INC. AND ACHILLES ACQUISITION SUBSIDIARY, LLC Dated as of November 19, 2012 This copy of the Agreement and Plan of Merger is filed as an exhibit to this Current Report on Form 8-K to provide information regarding its terms and it is n

AGREEMENT AND PLAN OF MERGER by and among BIOMIMETIC THERAPEUTICS, INC., WRIGHT MEDICAL GROUP, INC., ACHILLES MERGER SUBSIDIARY, INC. ACHILLES ACQUISITION SUBSIDIARY, LLC Dated as of November 19, 2012

EX-2.1 2 d441762dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among BIOMIMETIC THERAPEUTICS, INC., WRIGHT MEDICAL GROUP, INC., ACHILLES MERGER SUBSIDIARY, INC. AND ACHILLES ACQUISITION SUBSIDIARY, LLC Dated as of November 19, 2012 This copy of the Agreement and Plan of Merger is filed as an exhibit to this Current Report on Form 8-K to provide information regar

BioMimetic Therapeutics, Inc. Reports Third Quarter 2012 Financial Results

Exhibit 99.1 Contact: Kearstin Patterson Senior Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics, Inc. Reports Third Quarter 2012 Financial Results Franklin, Tenn. – November 5, 2012 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its corporate highlights and financial results as of and for the three a

Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2012 (November 5, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation)

Quarterly Report - 10-Q

10-Q 1 v32524810q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File

Other Events

8-K 1 v3239798k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2012 (September 13, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or oth

- REGISTRATION STATEMENT

As filed with the Securities and Exchange Commission on August 14, 2012 Registration No.

STATEMENT OF COMPUTATION OF RATIOS

Exhibit 12.1 STATEMENT OF COMPUTATION OF RATIOS Six months ended June 30, Years Ended December 31, 2012 2011 2010 2009 2008 2007 (in thousands, except for ratios) Earnings: Net loss from operations $ (12,573 ) $ (30,350 ) $ (34,564 ) $ (34,944 ) $ (36,752 ) $ (28,320 ) Add: Total fixed charges 16 209 6 547 303 58 Earnings (loss) as defined $ (12,557 ) $ (30,141 ) $ (34,558 ) $ (34,397 ) $ (36,449

BioMimetic Therapeutics, Inc. Reports Second Quarter 2012 Earnings Results

Exhibit 99.1 Contact: Kearstin Patterson Senior Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics, Inc. Reports Second Quarter 2012 Earnings Results Franklin, Tenn. – August 2, 2012 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its corporate highlights and financial results as of and for the three and

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2012 (August 2, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation) (Co

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from    to Commission File Number 000-51934 BioMimetic

BioMimetic Therapeutics Submits Augment® Bone Graft PMA Amendment to FDA Company to Host Conference Call at 4:30 EDT Today

Exhibit 99.1 Contact: Kearstin Patterson Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics Submits Augment® Bone Graft PMA Amendment to FDA Company to Host Conference Call at 4:30 EDT Today Franklin, Tenn. – July 9, 2012 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has submitted to the Food

Financial Statements and Exhibits, Other Events - 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2012 (July 9, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation) (Commis

- ANNUAL REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51934 A. Full title of the plan and

Timothy Daniels, MD Presents Results from Augment™ Injectable Bone Graft Clinical Trial

EX-99.1 2 v316633ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Kearstin Patterson Sr. Director, Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] Timothy Daniels, MD Presents Results from Augment™ Injectable Bone Graft Clinical Trial Franklin, Tenn. – June 21, 2012 - Dr. Timothy Daniels, associate professor of orthopedic surgery at the University of To

Financial Statements and Exhibits, Other Events

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2012 (June 21, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation) (Comm

Mandatory Disclosure Statement The following authors (or their immediate family members) have received something of value (≥ $500.00) from a commercial company or institution related directly or indirectly to the subject of this presentation, as note

EX-99.2 3 v316633ex99-2.htm EXHIBIT 99.2 Mandatory Disclosure Statement The following authors (or their immediate family members) have received something of value (≥ $500.00) from a commercial company or institution related directly or indirectly to the subject of this presentation, as noted below: a = research/institutional support, b = misc. non - income support, c = royalties, d = stock/options

BIOMIMETIC THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS June 7, 2012

exhibit 14.1 BIOMIMETIC THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS June 7, 2012 POLICY STATEMENT It is the policy of BioMimetic Therapeutics, Inc. (the “Company”) to conduct its affairs in accordance with all applicable laws, rules and regulations of the jurisdictions in which it does business. This Code of Business Conduct and Ethics (“Code”) applies to the Company’s associates (inclu

BioMimetic Therapeutics Announces Highlights from 2012 Annual Meeting of Stockholders

Exhibit 99.1 Contact: Kearstin Patterson Sr. Director, Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics Announces Highlights from 2012 Annual Meeting of Stockholders Franklin, Tenn. – June 7, 2012 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the results of its 2012 Annual Meeting of Stockholders that took plac

Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2012 (June 7, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorpo

-

begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0R(#`@;V)J#3P\+TQI;F5AF4@-34O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R`A(,4X`$XPT@P1($)-C.`HG/0Q,C`P[0;(,C.C$?\99?P`"#`#6H@?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@ M("`@#0HU-"`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``(>2094P,@` MDN5H0!9C@6(&AAL,W`R7!E+U!A9V4^/@UE;F1O8FH-#4@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I<&

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 v3127588k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 (May 9, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of

BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results

Exhibit 99.1 Contact: Kearstin Patterson Senior Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results Franklin, Tenn. – May 9, 2012 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its corporate highlights and financial results as of and for the three months

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51934 BioMimetic Th

2012 MANAGEMENT CASH INCENTIVE PLAN

EXHIBIT 10.1 2012 MANAGEMENT CASH INCENTIVE PLAN Russ Pagano and ** Russ Pagano and ** shall each be provided the following milestone-based cash incentive bonus opportunities, totaling a maximum of up to $100,000: (1) A single cash incentive bonus based upon the date of the ABG Approval (as defined below), in the amount of: (a) Eighty thousand dollars ($80,000); provided that ABG Approval occurs o

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 9, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation) (Commission

-

begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0P(#`@;V)J#3P\+TQI;F5AF4@-3,O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R`A(,4X`$XPT@P1(%)-A`(E/,0Q,C`S;0;(,C.C$?\8Y?P`"#`#7G`?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@ M("`@#0HU,B`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``(>'P94P,@` MDN5H0!9C@6(&AAL,W`Q7!E+U!A9V4^/@UE;F1O8FH-#,@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I<&

BioMimetic Therapeutics Inc. 401(k) Profit Sharing Plan & Trust PPA AMENDMENT

BioMimetic Therapeutics Inc. 401(k) Profit Sharing Plan & Trust PPA AMENDMENT WHEREAS, BioMimetic Therapeutics, Inc. (the "Company") maintains the BioMimetic Therapeutics Inc. 401(k) Profit Sharing Plan & Trust (the "Plan") for the benefit of certain of its employees; and WHEREAS, Pursuant to Section 13.01 of the Plan, the Company desires to amend the Plan; NOW, THEREFORE, the Plan is hereby amend

ADOPTION AGREEMENT #001 NON-STANDARDIZED 401(K)/PROFIT SHARING PLAN

ADOPTION AGREEMENT #001 NON-STANDARDIZED 401(K)/PROFIT SHARING PLAN The undersigned adopting employer hereby adopts this Plan and its related Trust.

- FORM S-8

Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 62-1786244 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification Number) 389 Nichol Mill Lane, Franklin, Tennessee 37067

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2012 (March 13, 2012) BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation) (Co

BioMimetic Therapeutics, Inc. Reports Fourth Quarter and Year-End 2011 Earnings Results

Exhibit 99.1 Contact: Kearstin Patterson Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics, Inc. Reports Fourth Quarter and Year-End 2011 Earnings Results Franklin, Tenn. – March 13, 2012 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and twelve months ende

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51934 BioMimetic Therapeutics, I

Subsidiary Jurisdiction of Incorporation BioMimetic Therapeutics Limited England and Wales BioMimetic Therapeutics Pty Ltd. Australia BioMimetic Therapeutics Canada, Inc. Canada BioMimetic Therapeutics USA, Inc. United States

EXHIBIT 21.1 Subsidiary Jurisdiction of Incorporation BioMimetic Therapeutics Limited England and Wales BioMimetic Therapeutics Pty Ltd. Australia BioMimetic Therapeutics Canada, Inc. Canada BioMimetic Therapeutics USA, Inc. United States

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 29, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation) (Commis

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 21, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation) (Commis

AMENDMENT TO AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT

AMENDMENT TO AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT This Amendment to the Amended and Restated Manufacturing and Supply Agreement (the “Amendment”) is entered into as of the 2nd day of February, 2012 and is deemed to have come into effect on 1 January 2012 (the “Effective Date”), by and among Novartis Vaccines and Diagnostics, Inc.

BMTI / Biomimetic Therapeutics, Inc. / Clearbridge Investments, LLC - BIOMIM Passive Investment

Securities and Exchange Commission Washington, D. C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 ) BioMimetic Therapeutics Inc Common Stock CUSIP Number 09064X101 Date of Event Which Requires Filing of this Statement: December 31, 2011 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1(b) [ ] Rule 13d-1(c) [

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-51934 62-1786244 (State or Other Jurisdiction of Incorporation) (Commiss

BioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS Meetings Company Announces Results of its Augment® Rotator Cuff Graft Clinical Trial

Contact: Kearstin Patterson Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) kpatterson@biomimetics.

BioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOS

Contact: Kearstin Patterson Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) kpatterson@biomimetics.

BMTI / Biomimetic Therapeutics, Inc. / TCW GROUP INC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* BioMimetic Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09064X101 (CUSIP Number) 12/31/2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Other Events - 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation) (Com

BioMimetic Therapeutics Receives Augment® Bone Graft PMA Response Letter from FDA Company to Host Conference Call at 4:30 EST Today

Exhibit 99.1 Contact: Kearstin Patterson Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics Receives Augment® Bone Graft PMA Response Letter from FDA Company to Host Conference Call at 4:30 EST Today Franklin, Tenn. – January 3, 2012 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it received a com

BioMimetic Therapeutics Announces Approval to Market GEM 21S® in the European Union

Exhibit 99.2 Contact: Kearstin Patterson Director of Corporate Communications 615-236-4419 (office) 615-517-6112 (mobile) [email protected] BioMimetic Therapeutics Announces Approval to Market GEM 21S® in the European Union Franklin, Tenn. – January 3, 2012 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today receipt of the CE Mark approval of GEM 21S® Growth factor Enhanced Mat

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2012 BIOMIMETIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51934 62-1786244 (State or other jurisdiction of incorporation) (Comm